Market Closed -
Bombay S.E.
11:00:54 02/07/2024 BST
|
5-day change
|
1st Jan Change
|
470.4
INR
|
-0.40%
|
|
+1.70%
|
+18.79%
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
44,769
|
29,213
|
33,502
|
48,229
|
43,367
|
42,564
|
Enterprise Value (EV)
1 |
40,550
|
24,961
|
28,332
|
42,822
|
38,304
|
38,036
|
P/E ratio
|
25.8
x
|
17.2
x
|
14.1
x
|
16.1
x
|
20
x
|
22
x
|
Yield
|
-
|
-
|
0.41%
|
-
|
-
|
-
|
Capitalization / Revenue
|
4.16
x
|
2.68
x
|
2.49
x
|
3.62
x
|
2.84
x
|
2.39
x
|
EV / Revenue
|
3.77
x
|
2.29
x
|
2.11
x
|
3.21
x
|
2.51
x
|
2.13
x
|
EV / EBITDA
|
17.5
x
|
10.9
x
|
9.5
x
|
13.1
x
|
15.6
x
|
15.7
x
|
EV / FCF
|
40.1
x
|
37.6
x
|
18.6
x
|
32.7
x
|
159
x
|
349
x
|
FCF Yield
|
2.49%
|
2.66%
|
5.39%
|
3.05%
|
0.63%
|
0.29%
|
Price to Book
|
3.44
x
|
2.02
x
|
2.17
x
|
2.78
x
|
2.22
x
|
2.15
x
|
Nbr of stocks (in thousands)
|
177,833
|
174,403
|
170,973
|
168,810
|
168,810
|
165,910
|
Reference price
2 |
251.8
|
167.5
|
196.0
|
285.7
|
256.9
|
256.6
|
Announcement Date
|
25/05/18
|
31/08/19
|
08/09/20
|
06/09/21
|
29/08/22
|
04/09/23
|
Fiscal Period: Maart |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
10,751
|
10,907
|
13,442
|
13,332
|
15,279
|
17,838
|
EBITDA
1 |
2,313
|
2,293
|
2,981
|
3,267
|
2,461
|
2,424
|
EBIT
1 |
1,979
|
1,978
|
2,673
|
2,962
|
2,164
|
2,120
|
Operating Margin
|
18.41%
|
18.13%
|
19.88%
|
22.22%
|
14.16%
|
11.89%
|
Earnings before Tax (EBT)
1 |
2,406
|
2,366
|
3,200
|
3,877
|
2,894
|
2,578
|
Net income
1 |
1,735
|
1,698
|
2,399
|
3,013
|
2,164
|
1,940
|
Net margin
|
16.14%
|
15.57%
|
17.85%
|
22.6%
|
14.16%
|
10.88%
|
EPS
2 |
9.758
|
9.735
|
13.94
|
17.73
|
12.82
|
11.67
|
Free Cash Flow
1 |
1,011
|
664.1
|
1,526
|
1,308
|
241
|
109.1
|
FCF margin
|
9.4%
|
6.09%
|
11.35%
|
9.81%
|
1.58%
|
0.61%
|
FCF Conversion (EBITDA)
|
43.68%
|
28.96%
|
51.18%
|
40.04%
|
9.8%
|
4.5%
|
FCF Conversion (Net income)
|
58.24%
|
39.11%
|
63.61%
|
43.41%
|
11.14%
|
5.62%
|
Dividend per Share
|
-
|
-
|
0.8000
|
-
|
-
|
-
|
Announcement Date
|
25/05/18
|
31/08/19
|
08/09/20
|
06/09/21
|
29/08/22
|
04/09/23
|
Fiscal Period: March |
2022 Q1
|
2022 Q2
|
2022 Q3
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
---|
Net sales
1 |
4,475
|
3,976
|
3,418
|
4,947
|
4,450
|
4,093
|
EBITDA
|
1,155
|
712.1
|
478.1
|
780
|
673.2
|
-
|
EBIT
|
-
|
-
|
-
|
-
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/08/21
|
11/11/21
|
09/02/22
|
04/08/22
|
14/11/22
|
09/02/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
4,220
|
4,251
|
5,170
|
5,407
|
5,063
|
4,529
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
1,011
|
664
|
1,526
|
1,308
|
241
|
109
|
ROE (net income / shareholders' equity)
|
13.6%
|
12.5%
|
16%
|
18.4%
|
11.7%
|
9.84%
|
ROA (Net income/ Total Assets)
|
8.32%
|
7.86%
|
9.68%
|
9.82%
|
6.4%
|
5.75%
|
Assets
1 |
20,846
|
21,601
|
24,792
|
30,673
|
33,815
|
33,773
|
Book Value Per Share
2 |
73.20
|
82.90
|
90.50
|
103.0
|
116.0
|
119.0
|
Cash Flow per Share
2 |
1.610
|
1.140
|
1.750
|
1.800
|
2.230
|
1.440
|
Capex
1 |
370
|
427
|
312
|
625
|
1,325
|
1,131
|
Capex / Sales
|
3.44%
|
3.92%
|
2.32%
|
4.69%
|
8.67%
|
6.34%
|
Announcement Date
|
25/05/18
|
31/08/19
|
08/09/20
|
06/09/21
|
29/08/22
|
04/09/23
|
|
1st Jan change
|
Capi.
|
---|
| +18.79% | 921M | | +55.55% | 823B | | +42.31% | 641B | | -6.83% | 352B | | +17.15% | 324B | | +7.09% | 301B | | +14.02% | 241B | | +1.64% | 223B | | +13.66% | 218B | | +7.87% | 167B |
Other Pharmaceuticals
|